From: CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
Immunotherapy type | Immunotherapy targets | Disease | Treatment | Phase | Clinical trial identifier | Sponsor |
---|---|---|---|---|---|---|
Checkpoint inhibitor | CD155 (PVR), PD-1 | Solid tumors | COM701, Opdivo (nivolumab) | 1 | NCT03667716 | Compugen Ltd, Bristol-Myers Squibb |
Oncolytic virus | CD155 (PVR) | Melanoma | PVSRIPO | 1 | NCT03712358 | Istari Oncology, Inc., Duke University |
Oncolytic virus | CD155 (PVR) | Glioblastoma, malignant glioma | PVSRIPO | 1 | NCT01491893 | Istari Oncology, Inc., National Cancer Institute (NCI), Brain Tumor Research Charity Grant, Duke University |
Monoclonal antibody | TIGIT, PD-1 | Metastatic solid tumors | BGB-A1217, tislelizumab | 1 | NCT04047862 | BeiGene |
Monoclonal antibody | TIGIT, PD-L1 | Non-small cell lung cancer | Atezolizumab, MTIG7192A | 2 | NCT03563716 | Genentech, Inc. |
Monoclonal antibody | TIGIT, PD-L1 | Small cell lung cancer | Tiragolumab atezolizumab, carboplatin, etoposide | 3 | NCT04256421 | Hoffmann-La Roche |
Monoclonal antibody | TIGIT, PD-L1 | Non-small cell lung cancer | Atezolizumab, tiragolumab | 3 | NCT04294810 | Hoffmann-La Roche |
Monoclonal antibody | TIGIT, PD-1 | Solid tumors | AB154, AB122 | 1 | NCT03628677 | Arcus Biosciences, Inc. |
Monoclonal antibody | TIGIT, PD-1, A2aR/A2bR | Non-small cell lung cancer | Zimberelimab, AB154, AB928 | 2 | NCT04262856 | Arcus Biosciences, Inc. |
Monoclonal antibody | TIGIT, D-L1, MEK1/2, VEGFR2, CXCR4, DPP-4 | Gastric adenocarcinoma, esophageal carcinoma | 5-Fluorouracil (5-FU), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, PEGPH20, BL-8040, linagliptin, cisplatin, tiragolumab | 1/2 | NCT03281369 | Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd. |